278,796$ 17,387$
296,183$
234,757$ 16,507$
251,26419%5%18%NUVIGIL58,863-58,86335,614-35,61465-65GABITRIL10,7341,24911,98314,0421,51515,557(24)(18)(23)Other Proprietary CNS-2,6982,698-3,6473,647-(26)(26)Generic CNS-8,7638,763-2,7072,707-224224CNS 348,39330,097378,490284,41324,376308,789222323PainProprietary PainFENTORA44,8767,09851,97436,8771,67638,5532232435AMRIX28,768-28,76830,628-30,628(6)-(6)Other Proprietary Pain-7272-5050-4444Generic PainACTIQ18,34916,53834,88718,72618,94937,675(2)(13)(7)Generic OTFC8,529-8,52916,198-16,198(47)-(47)Other Generic Pain-20,40620,406-2,6962,696-657657Pain100,52244,114144,636102,42923,371125,800(2)8915OncologyProprietary OncologyTREANDA108,573-108,57361,563-61,56376-76Other Proprietary Oncology4,93518,96623,9014,75221,62726,3794(12)(9)Generic Oncology-7,5887,588-6,2556,255-2121Oncology113,50826,554140,06266,31527,88294,19771(5)49OtherOther Proprietary3,8901,7015,5914,268-4,268(9)10031Other Generic2,54093,44095,9802,54627,33829,884-242221Other6,43095,141101,5716,81427,33834,152(6)248197$
568,853$ 195,906$
764,759$
459,971$ 102,967$
562,93824%90%36%Year Ended%December 31,Increase20102009(Decrease)United StatesEuropeTotalUnited StatesEuropeTotalUnited StatesEuropeTotalSales:CNSProprietary CNSPROVIGIL$ 1,059,698$ 64,796$ 1,124,494$
961,070$ 63,618$ 1,024,68810%2%10%NUVIGIL186,190-186,19073,391-73,391154-154GABITRIL39,7284,76044,48851,1005,38656,486(22)(12)(21)Other Proprietary CNS-10,93610,936-13,29213,292-(18)(18)Generic CNS-28,25728,257-10,78510,785-162162CNS 1,285,616108,7491,394,3651,085,56193,0811,178,642181718PainProprietary PainFENTORA159,58522,037181,622136,5634,114140,6771743629AMRIX109,235-109,235114,435-114,435(5)-(5)Other Proprietary Pain-271271-267267-11Generic PainACTIQ63,93066,951130,88175,41871,527146,945(15)(6)(11)Generic OTFC41,138-41,13883,032-83,032(50)-(50)Other Generic Pain-63,14463,144-8,9548,954-605605Pain373,888152,403526,291409,44884,862494,310(9)806Oncolo
'/>"/>SOURCE Cephalon, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related medicine technology :1.
Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics2.
ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology3.
Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder4.
Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors5.
Cephalon to Webcast Investor Day6.
Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL7.
Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations8.
Cephalon Exercises its Option to Acquire BioAssets Development Corporation9.
Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL10.
Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform11.
Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.